Breaking News Instant updates and real-time market news.

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

13:45
10/21/18
10/21
13:45
10/21/18
13:45

Mirati announces updated data from ongoing trial of single agent sitravatinib

Mirati Therapeutics announced the completed stage 1 safety and efficacy data from the ongoing Phase 1b clinical trial of single agent sitravatinib in patients with certain classes of oncogenic mutations. The data for a cohort of patients harboring CBL mutations were presented in a proffered poster session at the European Society for Medical Oncology 2018 Congress in Munich, Germany. The presentation provided an update from the pre-planned expansion cohort of the Phase 1b clinical trial of single agent sitravatinib in patients with CBL inactivating mutations. Eight patients were evaluable as of the data cut-off on August 27, 2018. In the subset of evaluable NSCLC patients, 1/2 confirmed partial responses were observed with 2/2 patients experiencing tumor regression. In the subset of evaluable melanoma patients, 1/2 confirmed partial responses in evaluable patients were observed with 1/2 patients experiencing tumor regression. In the subset of evaluable patients with other solid tumors, 2/4 had stable disease with 2/4 experiencing tumor regression. CBL mutations are present in 1.5% of NSCLC, 3.5% of melanoma, and 2% of cancers of unknown origin.

  • 21

    Oct

  • 22

    Oct

MRTX Mirati Therapeutics
$40.04

-1.82 (-4.35%)

07/09/18
OPCO
07/09/18
NO CHANGE
Target $62
OPCO
Outperform
Mirati Therapeutics price target raised to $62 from $35 at Oppenheimer
Oppenheimer analyst Leah Rush Cann raised her price target for Mirati Therapeutics to $62 from $35 to account for an increased average forward price-to-sales multiple of the biotechnology sector. The analyst reiterates an Outperform rating on the shares.
07/20/18
HCWC
07/20/18
NO CHANGE
Target $63
HCWC
Buy
Mirati Therapeutics price target raised to $63 from $42 at H.C. Wainwright
H.C. Wainwright analyst Edward White raised his price target for Mirati Therapeutics to $63 to reflect a higher probability of success for sitravatinib. The analyst now applies a 45% probability of success for sitravatinib monotherapy and projects revenues of $407M, $448M and $179M for sitravatinib in combination with checkpoint therapy, sitravatinib as a single agent and mocetinostat, respectively, in 2027. He keeps a Buy rating on Mirati Therapeutics.
09/17/18
GUGG
09/17/18
INITIATION
Target $54
GUGG
Neutral
Mirati Therapeutics initiated with a Neutral at Guggenheim
Target $54.
09/27/18
COWN
09/27/18
NO CHANGE
COWN
Outperform
Mirati Therapeutics weakness a buying opportunity, says Cowen
Cowen analyst Chris Sibutani said he sees the pullback in Mirati Therapeutics shares as an attractive buying opportunity and reiterates his Outperform rating on the stock. There was never a reason to expect that Mirati's data was under consideration for a late-breaking abstract presentation at ESMO, Sibutani tells investors. He expects management to share their plans for the sitravatinib + nivolumab pivotal study program at the ESMO meeting after data is presented on Monday, October 22. The analyst maintains an Outperform rating on Mirati shares.

TODAY'S FREE FLY STORIES

13:35
03/18/19
03/18
13:35
03/18/19
13:35
General news
U.S. corporate bond update: a couple of issuers are jumping in »

U.S. corporate bond…

CCI

Crown Castle

$124.05

-1.03 (-0.82%)

13:35
03/18/19
03/18
13:35
03/18/19
13:35
Options
Crown Castle put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:35
03/18/19
03/18
13:35
03/18/19
13:35
General news
Treasury Option Action: call spread liquidation »

Treasury Option Action:…

FB

Facebook

$159.31

-6.68 (-4.02%)

13:33
03/18/19
03/18
13:33
03/18/19
13:33
Periodicals
Blumenthal wants Facebook probe after live stream of mosque attack, NY Post says »

Senator Richard…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 04

    Apr

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

, SPX

S&P 500

$0.00

(0.00%)

13:30
03/18/19
03/18
13:30
03/18/19
13:30
Periodicals
U.K. speaker says parliament won't vote again on Brexit deal, WSJ reports »

John Bercow, speaker of…

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$281.92

0.61 (0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNL

Global Net Lease

$18.38

-0.1 (-0.54%)

13:29
03/18/19
03/18
13:29
03/18/19
13:29
Conference/Events
Global Net Lease management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 27

    Mar

  • 28

    Mar

  • 15

    Apr

NVRO

Nevro

$44.31

0.56 (1.28%)

13:27
03/18/19
03/18
13:27
03/18/19
13:27
Conference/Events
Nevro management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 21

    Mar

NVRO

Nevro

$44.15

0.4 (0.91%)

13:27
03/18/19
03/18
13:27
03/18/19
13:27
Conference/Events
Nevro management to meet with SVB Leerink »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 21

    Mar

APYX

Apyx Medical

$7.93

0.005 (0.06%)

13:25
03/18/19
03/18
13:25
03/18/19
13:25
Conference/Events
Apyx Medical management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

T

AT&T

$30.77

0.09 (0.29%)

13:24
03/18/19
03/18
13:24
03/18/19
13:24
Periodicals
Kevin Tsujihara ousted as Warner Bros. CEO, CNBC reports »

Kevin Tsujihara has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 20

    Mar

  • 24

    Apr

  • 26

    Apr

  • 20

    May

CXP

Columbia Property

$21.99

-0.13 (-0.59%)

13:21
03/18/19
03/18
13:21
03/18/19
13:21
Conference/Events
Columbia Property management to meet with JMP Securities »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

BSX

Boston Scientific

$37.77

-2.38 (-5.93%)

13:20
03/18/19
03/18
13:20
03/18/19
13:20
Options
Quarter million dollar block of calls sold to open in Boston Scientific »

Quarter million dollar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

  • 28

    May

MIK

Michaels

$11.72

0.04 (0.34%)

, DSW

DSW

$25.05

-0.34 (-1.34%)

13:19
03/18/19
03/18
13:19
03/18/19
13:19
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

MIK

Michaels

$11.72

0.04 (0.34%)

DSW

DSW

$25.05

-0.34 (-1.34%)

HDS

HD Supply

$42.88

-0.12 (-0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 25

    Mar

  • 26

    Mar

  • 27

    Mar

REGN

Regeneron

$408.15

-6.03 (-1.46%)

, DERM

Dermira

$12.46

5.63 (82.43%)

13:17
03/18/19
03/18
13:17
03/18/19
13:17
On The Fly
Dermira rises, Regeneron slips on eczema treatment study results »

Shares of Dermira (DERM)…

REGN

Regeneron

$408.15

-6.03 (-1.46%)

DERM

Dermira

$12.46

5.63 (82.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 13

    May

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
03/18/19
03/18
13:17
03/18/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
03/18/19
03/18
13:16
03/18/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBCP

Home Bancorp

$36.50

0.59 (1.64%)

13:14
03/18/19
03/18
13:14
03/18/19
13:14
Hot Stocks
Home Bancorp CEO John Bordelon sells over $232K shares of company stock »

Home Bancorp CEO John…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ELAN

Elanco

$31.38

0.69 (2.25%)

13:14
03/18/19
03/18
13:14
03/18/19
13:14
Periodicals
Elanco tells Bloomberg CEO not planing to sell shares at lockup »

Elanco CEO Jeffrey…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

APEN

Apollo Endosurgery

$3.29

-0.06 (-1.79%)

13:13
03/18/19
03/18
13:13
03/18/19
13:13
Recommendations
Apollo Endosurgery analyst commentary  »

Piper says Apollo's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

  • 18

    May

  • 28

    May

QQQ

Invesco QQQ Trust

$178.07

0.1542 (0.09%)

13:10
03/18/19
03/18
13:10
03/18/19
13:10
Options
50K Invesco QQQ Jun 188 - 192 call spreads sold at 95c »

50K Invesco QQQ Jun 188 -…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CARS

Cars.com

$22.75

0.04 (0.18%)

13:05
03/18/19
03/18
13:05
03/18/19
13:05
Options
Cars.com call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:05
03/18/19
03/18
13:05
03/18/19
13:05
General news
FOMC Forecast revisions »

FOMC Forecast revisions…

AIR

AAR Corp.

$35.01

0.92 (2.70%)

13:01
03/18/19
03/18
13:01
03/18/19
13:01
Hot Stocks
AAR awarded $10.8M order from USAF to produce cargo pallets »

AAR has been awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

MYL

Mylan

$28.32

0.24 (0.85%)

12:51
03/18/19
03/18
12:51
03/18/19
12:51
Hot Stocks
Mylan Institutional LLC initiates voluntary recall of Levoleucovorin Injection »

Mylan Institutional LLC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LTS

Ladenburg Thalmann

$2.99

0.03 (1.01%)

12:50
03/18/19
03/18
12:50
03/18/19
12:50
Recommendations
Ladenburg Thalmann analyst commentary at Barrington »

Ladenburg Thalmann price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.